These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24964403)

  • 21. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
    J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Giacomet V; Bernardi S; Esposito S; Rosso R; Giaquinto C; Badolato R; Guarino A; Maccabruni A; Masi M; Cellini M; Salvini F; Di Bari C; Dedoni M; Dodi I; de Martino M;
    Acta Paediatr; 2012 Jul; 101(7):e287-95. PubMed ID: 22452359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful simplification of HAART in patients with acute primary HIV infection.
    Sinicco A; Bonora S; Arnaudo I; Zeme DA; Audagnotto S; Raiteri R; Di Perri G
    J Biol Regul Homeost Agents; 2002; 16(1):69-72. PubMed ID: 12003178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.
    Darcis G; Maes N; Pasternak AO; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Elmoussaoui M; Fombellida K; Vaira D; Moutschen M
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.
    Navarro J; Caballero E; Curran A; Burgos J; Ocaña I; Falcó V; Torrella A; Pérez M; Ribera E; Crespo M
    Antivir Ther; 2016; 21(4):345-52. PubMed ID: 26756461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
    Mocroft A; Bannister WP; Kirk O; Kowalska JD; Reiss P; D'Arminio-Monforte A; Gatell J; Fisher M; Trocha H; Rakhmanova A; Lundgren JD;
    Antivir Ther; 2012; 17(7):1291-300. PubMed ID: 23013779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study.
    Boillat-Blanco N; Darling KE; Taffe P; Osih R; Strahm C; Adami M; Elzi L; Daou S; Fehr J; Wandeler G; Cavassini M
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):180-9. PubMed ID: 23187939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE).
    Cheng CY; Luo YZ; Wu PY; Liu WC; Yang SP; Zhang JY; Cheng SH; Hung CC
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19785. PubMed ID: 25397529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal viral load outcomes of adults with HIV after detectable viremia on tenofovir, lamivudine, and dolutegravir.
    Sodeke O; Milligan K; Ezeuko I; Oladipo A; Emeh A; Bashorun A; Orisawayi O; Danjuma S; Onotu D; Boyd AM; Abutu A; Chun H; Vallabhaneni S
    AIDS; 2024 Sep; 38(11):1714-1719. PubMed ID: 38870005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].
    Palacios R; Senise JF; Vaz MJ; Castelo A
    Enferm Infecc Microbiol Clin; 2008; 26(7):411-5. PubMed ID: 18842235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
    Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.